Skip to main content

Acumen Pharmaceuticals, Inc.

ABOS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001576885

No open-market purchases or sales by Acumen Pharmaceuticals, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $127.8M in total; no superinvestor holds it.

Q1 2025 vs. Q4 2024

How the institutions holding Acumen Pharmaceuticals, Inc. changed between Q4 2024 and Q1 2025.

All holders in Q1 2025All holders in Q4 2024

13F holders of ABOS: Q4 2024 compared with Q1 2025
MeasureQ4 2024Of which not filed for Q1 2025Q1 2025Change
Holders80181+2
Shares42.5M78.4K40.3M−2.19M (−5.1%)
Value$73.2M$134.9K$44.8M−$28.2M (−38.6%)

1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (11)

Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q1 2025 but not at the end of Q4 2024.

Institutions new to ABOS in Q1 2025
InstitutionSharesValue% of portfolio
Nuveen, LLC78,446$86.3K0.00%
AQR Capital Management LLC41,735$45.9K0.00%
Thoroughbred Financial Services, LLC15,500$17.0K0.00%
Two Sigma Securities, LLC11,879$13.1K0.00%
The PNC Financial Services Group, Inc.4,446$4.89K0.00%
Meeder Asset Management Inc1,584$1.74K0.00%
N.E.W. Advisory Services LLC598$6580.00%
EverSource Wealth Advisors, LLC486$5350.00%
Rise Advisors, LLC373$4100.00%
Coldstream Capital Management Inc311$3430.00%
True Wealth Design, LLC29$320.00%

Sold out (9)

Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.

Institutions that sold out of ABOS in Q1 2025
InstitutionShares, Q4 2024Value, Q4 2024
Rock Springs Capital Management LP1,838,916$3.16M
American Century Companies Inc54,278$93.4K
Prelude Capital Management, LLC48,414$83.3K
Atom Investors LP33,678$57.9K
Verition Fund Management LLC19,445$33.4K
Susquehanna Fundamental Investments, LLC14,731$25.3K
ProShare Advisors LLC11,812$20.3K
Citadel Advisors LLC9,597$16.5K
Nisa Investment Advisors, LLC356$612

Not filed for Q1 2025 yet (1)

Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ABOS in Q4 2024 that haven't filed for Q1 2025
InstitutionShares, Q4 2024Value, Q4 2024
Nuveen Asset Management, LLC78,446$134.9K